Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PROTAGONIST THERAPEUTICS, INC.

(PTGX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

PROTAGONIST THERAPEUTICS, INC : Other Events, Financial Statements and Exhibits (form 8-K)

09/17/2021 | 05:31pm EDT
Item 8.01 Other Events.



On September 17, 2021, Protagonist Therapeutics, Inc. (the "Company") issued a press release announcing that the Company's clinical studies for rusfertide, an investigational product candidate currently in development, have been placed on a clinical hold. A copy of the press release titled "Protagonist Therapeutics Reports FDA Clinical Hold on Rusfertide Clinical Development Program" is attached hereto as Exhibit 99.1 and incorporated by reference herein. The Company has begun to provide the FDA with the information requested, including additional information related to four cases of cancer observed to date across all rusfertide clinical trials. These four cases relate to distinct forms of cancer and were assessed to be unrelated to rusfertide due to a preexisting condition or natural disease progression.

In accordance with General Instruction B.2 of Form 8-K, the information in this Item 8.01, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits





(d) Exhibits.



Exhibit                                   Description

  99.1       Press release, dated September 17, 2021, titled "Protagonist
           Therapeutics Reports FDA Clinical Hold on Rusfertide Clinical Development
           Program"
  104      Cover Page Interactive Data File (embedded within the Inline XBRL
           document).

© Edgar Online, source Glimpses

All news about PROTAGONIST THERAPEUTICS, INC.
10/13PROTAGONIST THERAPEUTICS : JMP Securities Adjusts Price Target on Protagonist Therapeutics..
MT
10/13NORTH AMERICAN MORNING BRIEFING : Stock Futures -3-
DJ
10/12PROTAGONIST THERAPEUTICS : Shares Drop on Elevated Volume
MT
10/12PROTAGONIST THERAPEUTICS : JMP Securities Adjusts Price Target on Protagonist Therapeutics..
MT
10/12WALL STREET STOCK EXCHANGE : It's just a period of market normalization
10/12PROTAGONIST THERAPEUTICS : SVB Leerink Adjusts Protagonist Therapeutics' Price Target to $..
MT
10/12PROTAGONIST THERAPEUTICS : JPMorgan Upgrades Protagonist Therapeutics to Overweight From N..
MT
10/12PROTAGONIST THERAPEUTICS : to Present at the Jefferies Next Generation IBD Therapeutics Su..
PR
10/12ANALYST RECOMMENDATIONS : Cigna, Halliburton, Nike, Nio, Trex...
10/11Health Care Stocks Sliding in Late Monday Trading
MT
More news
Analyst Recommendations on PROTAGONIST THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2021 14,2 M - -
Net income 2021 -117 M - -
Net cash 2021 250 M - -
P/E ratio 2021 -12,1x
Yield 2021 -
Capitalization 1 476 M 1 476 M -
EV / Sales 2021 86,2x
EV / Sales 2022 29,8x
Nbr of Employees 101
Free-Float 98,6%
Chart PROTAGONIST THERAPEUTICS, INC.
Duration : Period :
Protagonist Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PROTAGONIST THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 31,05 $
Average target price 58,29 $
Spread / Average Target 87,7%
EPS Revisions
Managers and Directors
Dinesh V. Patel President, Chief Executive Officer & Director
Donald A. Kalkofen Chief Financial Officer
Harold E. Selick Chairman
Mark L. Smythe Vice President-Technology
David Y. Liu Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
PROTAGONIST THERAPEUTICS, INC.54.02%1 476
MODERNA, INC.225.04%137 066
LONZA GROUP AG32.03%60 786
IQVIA HOLDINGS INC.42.23%48 830
SEAGEN INC.-0.71%31 638
CELLTRION, INC.-38.86%25 233